Table 5.
Generic name | Trade name | Source | Indications |
---|---|---|---|
Daclizumab IV | ZenapaxTM | Humanized mAb | No longer manufactured |
Basiliximab IV | SimulectTM | Chimeric mAb | Not formally tested in MS |
Daclizumab-β SQ | ZinbrytaTM | Humanized mAb | Approved for RRMS |
IV = intravenous; SQ = subcutaneous; MS = multiple sclerosis; RRMS = relapsing-remitting MS